@Kinoxis_tx
@Kinoxis_Tx
Followers
281
Following
150
Media
13
Statuses
68
An Australian clinical stage biotech company focused on the development of novel therapeutics for the treatment of addiction and other CNS disorders.
Melbourne, Victoria
Joined October 2017
@Kinoxis_Tx is pleased to share that $14.5m in funding has been raised to support Phase 2 programs for lead drug asset KNX100. We would like to thank key investors for sharing and supporting our vision in treating #dementia and #substanceusedisorder. More: https://t.co/NDR7Vqv0H4
0
1
5
@Kinoxis_Tx is pleased to share that our CEO Hugh Alsop has been recognised as the CEO of the Year by Brooker Consulting, for his significant contribution to the life sciences industry. Congratulations to Hugh and all other award recipients! #leadershipaward
0
0
3
.@Kinoxis_Tx is excited to announce US$3.6m grant from @NIDAnews to fund the Phase 1 trial for lead drug #KNX100, targeted at addressing opioid withdrawal. Learn more about what this means for Kinoxis, KNX100 and those battling opioids: https://t.co/b3PPR0JHA1
#biotech #science
0
3
16
The approval of OPVEE today by the FDA is another tool in the battle against the opioid crisis. The development, approval and availability of new treatment options is an essential part of the solution to control the devastating harm caused from opioid use disorder.
The @US_FDA approved #Indivior PLC’s nalmefene nasal spray for the emergency treatment of confirmed or suspected opioid overdose. #FDA #IndiviorPLC #Opvee #DrugDevelopment #BioSpace
https://t.co/jm0A7iIFUy
0
0
2
We are joining forces with @Kinoxis_tx to develop first-in-class precision psychiatry treatments to improve the quality of life of people living with neuropsychiatric disorders. Learn more: https://t.co/lwua3CvKyn
#PrecisionPsychiatry #MentalHealth
4
13
22
It’s a proud day for @Kinoxis_tx, as we announce a partnership with @Boehringer to develop oxytocin-targeting therapeutics to help people with #neuropsychiatric disorders. Read about our partnership and the exciting science behind it here: https://t.co/k77RAIvHDy
2
1
31
Great to get the Kinoxis team together for a Christmas catch up. @BowenLabTweets @MichaelKassiou @iainsmcgregor
0
6
20
The Opioid crisis remains a key challenge for the US and a reminder to the Kinoxis team of the importance of our work as we continue development of new treatment options. Opioid crisis: Congress and Biden suggest radical change to War on Drugs approach
0
1
2
Chapter 10 in the new book "Oxytocin" is led by co-editor @tristanreekie and reviews all the molecules reported to be active in the oxytocin system https://t.co/IiM1YT5eEk Editors: E. Werry, @tristanreekie @MichaelKassiou
0
3
4
Well done Associate Professor Michael Bowen @BowenLabTweets of @BrainMind_Usyd and @Kinoxis_Tx, for being award the Prize for New Innovators in the 2021 Prime Minister’s Prizes for Science. Further motivation for our incredible team! @ScienceGovAu #pmprizes @UniseedFund
Congratulations to Associate Professor Michael Bowen @BowenLabTweets from @Sydney_Uni and @Kinoxis_Tx, recipient of the 2021 Prize for New Innovators. Outstanding! More: https://t.co/v0SBDgK8hi
#pmprizes
0
0
19
A great resource published recently by some of our collaborators at @Sydney_Uni. Targeting the oxytocin receptor in the brain holds so much promise for many neurological disorders & @Kinoxis_Tx is making great progress on several promising therapeutic candidates.
Interested in #oxytocin #research? The book "OXYTOCIN" edited by E. Werry, @tristanreekie & @MichaelKassiou just published with #Springer
https://t.co/qOsz58GoyS is a must read. #Mentalhealth #molecularbiology
@Sydney_DDI @SydneyChemistry @Sydney_Science @syd_health @Kinoxis_Tx
0
4
8
As 2020 comes to a close, Kinoxis is pleased to announce the completion of a $5m funding round from existing shareholders. @UniseedFund @Sydney_Uni
https://t.co/6zj3W4aGPD
linkedin.com
$5m funding round completed with existing shareholders Successful completion of key pre-clinical toxicology studies IND meeting and commencement of Phase 1 in first half of 2021 Additional drug...
0
2
11
Great to be working more closely with @BioCurate on biotech projects at the @unimelb . @cglennbegley
#seedingthefuture
https://t.co/DNUSgLq9XF
0
3
9
@Kinoxis_Tx is pleased to be sharing our story at the Emergence2020 event in Sydney today. Thanks @wholesaleinvest for a great event!
0
1
4
Australia's opioid crisis: Deaths rise as companies encourage doctors to prescribe https://t.co/HWft1waqSp via @theage
theage.com.au
Dispensing rates of opioids have skyrocketed as some become addicted via prescriptions then hit the dark web for their fix. Still governments have been slow to act.
0
1
2
The use of opioids to treat acute and chronic pain contributed to approximately 10.3 million people age 12 years and older in the U.S. who misused opioids in 2018. The #nihHEALinitiative is working to end the national opioid public health crisis.
heal.nih.gov
The NIH HEAL Initiative is an NIH-wide effort to speed scientific solutions to stem the national opioid public health crisis.
1
14
29
Kinoxis is a proud spin out of the University of Sydney - a great model, supported in our case by the team @UniseedFund
0
0
8
So great to have the Kinoxis research team together for lunch in one place today.
0
1
12